Posted by Michael Wonder on 05 Dec 2024
European Commission approves BeiGene’s Tevimbra for first-line treatment of advanced/metastatic oesophageal squamous cell carcinoma and gastric or gastro-oesophageal junction cancer
27 November 2024 - New indications based on two Phase 3 studies demonstrating statistically significant overall survival benefit for patients treated with Tevimbra in combination with chemotherapy
BeiGene today announced that the European Commission has approved Temvimbra (tislelizumab) in combination with chemotherapy for the first-line treatment of oesophageal squamous cell carcinoma and gastric or gastro-oesophageal junction adenocarcinoma.
